145 related articles for article (PubMed ID: 30396656)
1. Dedicated breast PET value to evaluate BI-RADS 4 breast lesions.
Graña-López L; Herranz M; Domínguez-Prado I; Argibay S; Villares A; Ruibal A; Vázquez-Caruncho M
Eur J Radiol; 2018 Nov; 108():201-207. PubMed ID: 30396656
[TBL] [Abstract][Full Text] [Related]
2. Reproducibility assessment of uptake on dedicated breast PET for noise discrimination.
Yuge S; Miyake KK; Ishimori T; Kataoka M; Matsumoto Y; Fujimoto K; Sugie T; Toi M; Nakamoto Y
Ann Nucl Med; 2023 Feb; 37(2):121-130. PubMed ID: 36434200
[TBL] [Abstract][Full Text] [Related]
3. Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ?
Graña-López L; Herranz M; Domínguez-Prado I; Argibay S; Villares Á; Vázquez-Caruncho M
Eur Radiol; 2020 Jan; 30(1):514-522. PubMed ID: 31375867
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic performance of dedicated breast positron emission tomography.
Hashimoto R; Akashi-Tanaka S; Watanabe C; Masuda H; Taruno K; Takamaru T; Ide Y; Kuwayama T; Kobayashi Y; Takimoto M; Nakamura S
Breast Cancer; 2022 Nov; 29(6):1013-1021. PubMed ID: 35768684
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer detection by dedicated breast positron emission tomography according to the World Health Organization classification of breast tumors.
Sasada S; Kimura Y; Masumoto N; Emi A; Kadoya T; Arihiro K; Okada M
Eur J Surg Oncol; 2021 Jul; 47(7):1588-1592. PubMed ID: 33685728
[TBL] [Abstract][Full Text] [Related]
6. Higher breast cancer conspicuity on dbPET compared to WB-PET/CT.
Nishimatsu K; Nakamoto Y; Miyake KK; Ishimori T; Kanao S; Toi M; Togashi K
Eur J Radiol; 2017 May; 90():138-145. PubMed ID: 28583624
[TBL] [Abstract][Full Text] [Related]
7. Dedicated breast PET for detecting residual disease after neoadjuvant chemotherapy in operable breast cancer: A prospective cohort study.
Sasada S; Masumoto N; Goda N; Kajitani K; Emi A; Kadoya T; Okada M
Eur J Surg Oncol; 2018 Apr; 44(4):444-448. PubMed ID: 29396328
[TBL] [Abstract][Full Text] [Related]
8. The feasibility of dedicated breast PET for the assessment of residual tumor after neoadjuvant chemotherapy.
Koyasu H; Goshima S; Noda Y; Nishibori H; Takeuchi M; Matsunaga K; Yamada T; Matsuo M
Jpn J Radiol; 2019 Jan; 37(1):81-87. PubMed ID: 30392134
[TBL] [Abstract][Full Text] [Related]
9. Quantitative DWI implemented after DCE-MRI yields increased specificity for BI-RADS 3 and 4 breast lesions.
Dijkstra H; Dorrius MD; Wielema M; Pijnappel RM; Oudkerk M; Sijens PE
J Magn Reson Imaging; 2016 Dec; 44(6):1642-1649. PubMed ID: 27273694
[TBL] [Abstract][Full Text] [Related]
10. Contrast-enhanced MR imaging in patients with BI-RADS 3-5 microcalcifications.
Cilotti A; Iacconi C; Marini C; Moretti M; Mazzotta D; Traino C; Naccarato AG; Piagneri V; Giaconi C; Bevilacqua G; Bartolozzi C
Radiol Med; 2007 Mar; 112(2):272-86. PubMed ID: 17361370
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral heterogeneity on dedicated breast positron emission tomography predicts malignancy grade of breast cancer.
Masumoto N; Kadoya T; Sasada S; Emi A; Arihiro K; Okada M
Breast Cancer Res Treat; 2018 Sep; 171(2):315-323. PubMed ID: 29779072
[TBL] [Abstract][Full Text] [Related]
12. Comparison of dedicated breast positron emission tomography and whole-body positron emission tomography/computed tomography images: a common phantom study.
Satoh Y; Motosugi U; Imai M; Onishi H
Ann Nucl Med; 2020 Feb; 34(2):119-127. PubMed ID: 31768819
[TBL] [Abstract][Full Text] [Related]
13. Assessment of BI-RADS category 4 lesions detected with screening mammography and screening US: utility of MR imaging.
Strobel K; Schrading S; Hansen NL; Barabasch A; Kuhl CK
Radiology; 2015 Feb; 274(2):343-51. PubMed ID: 25271857
[TBL] [Abstract][Full Text] [Related]
14. [Stereotactic Mammotome breast biopsy: routine clinical experience and correlation with BI-RADS--classification and histopathology].
Michel SC; Löw R; Singer G; Otto R; Hohl M; Kubik RA
Praxis (Bern 1994); 2007 Sep; 96(39):1459-74. PubMed ID: 17966279
[TBL] [Abstract][Full Text] [Related]
15. Can strain elastography combined with ultrasound breast imaging reporting and data system be a more effective method in the differentiation of benign and malignant breast lesions?
Arslan S; Uslu N; Ozturk FU; Akcay EY; Tezcaner T; Agildere AM
J Med Ultrason (2001); 2017 Oct; 44(4):289-296. PubMed ID: 28154989
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of combined BI-RADS analysis and Nakagami statistics of ultrasound echoes in the diagnosis of breast lesions.
Dobruch-Sobczak K; Piotrzkowska-Wróblewska H; Roszkowska-Purska K; Nowicki A; Jakubowski W
Clin Radiol; 2017 Apr; 72(4):339.e7-339.e15. PubMed ID: 28038779
[TBL] [Abstract][Full Text] [Related]
17. US and MRI in the evaluation of mammographic BI-RADS 4 and 5 microcalcifications.
Hrkac Pustahija A; Ivanac G; Brkljacic B
Diagn Interv Radiol; 2018 Jul; 24(4):187-194. PubMed ID: 30091708
[TBL] [Abstract][Full Text] [Related]
18. Rate of malignancy in MRI-detected probably benign (BI-RADS 3) lesions.
Spick C; Szolar DH; Baltzer PA; Tillich M; Reittner P; Preidler KW; Pinker-Domenig K; Helbich TH
AJR Am J Roentgenol; 2014 Mar; 202(3):684-9. PubMed ID: 24555608
[TBL] [Abstract][Full Text] [Related]
19. Which type of breast cancers is undetectable on ring-type dedicated breast PET?
Sasada S; Masumoto N; Goda N; Kajitani K; Emi A; Kadoya T; Okada M
Clin Imaging; 2018; 51():186-191. PubMed ID: 29859482
[TBL] [Abstract][Full Text] [Related]
20. A Pivotal Study of Optoacoustic Imaging to Diagnose Benign and Malignant Breast Masses: A New Evaluation Tool for Radiologists.
Neuschler EI; Butler R; Young CA; Barke LD; Bertrand ML; Böhm-Vélez M; Destounis S; Donlan P; Grobmyer SR; Katzen J; Kist KA; Lavin PT; Makariou EV; Parris TM; Schilling KJ; Tucker FL; Dogan BE
Radiology; 2018 May; 287(2):398-412. PubMed ID: 29178816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
